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The amyloidoses are the prototype gain of toxic function protein misfolding diseases. As such, sev-
eral naturally occurring animal models and their inducible variants provided some of the ﬁrst
insights into these disorders of protein aggregation. With greater analytic knowledge and the
increasing ﬂexibility of transgenic and gene knockout technology, new models have been generated
allowing the interrogation of phenomena that have not been approachable in more reductionist sys-
tems, i.e. behavioral readouts in the neurodegenerative diseases, interactions among organ systems
in the transthyretin amyloidoses and taking pre-clinical therapeutic trials beyond cell culture. The
current review describes the features of both transgenic and non-transgenic models and discusses
issues that appear to be unresolved even when viewed in their organismal context.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Why do we need animal models of protein misfolding
disorders?
Historically, when it was technically difﬁcult to study human
disease in detail, except at the autopsy table, we searched for other
means of obtaining useful information and many diseases were
modeled (with more or less ﬁdelity) in animals. High resolution
imaging, sensitive comprehensive physiologic monitoring capabil-
ity and convenient multiple detailed analyses of plasma and cellu-
lar components of the body ﬂuids have allowed us to deﬁne many
physiologic parameters in living humans regardless of their state of
health. On the molecular level we can study the attributes of fold-
ing and misfolding in inﬁnite detail using puriﬁed proteins in the
test tube in an experimentally convenient time frame. We can
add small molecules, peptides, and vary conditions so that we
accelerate or inhibit ﬁbril formation. We can derive mathematical
models that explain why any given precursor goes from a soluble
to an insoluble state and determine the precise nature of that state
in atomic detail. Having done all that it is still not possible to ex-chemical Societies. Published by Eplain why an amyloidogenic protein, perhaps present from concep-
tion in roughly the same concentrations, does not form tissue
deposits until late in life. Nor can we explain why deposits occur
in some tissues and not in others and why in some people and
not in others. Finally, while it is possible to expose a cell to a poten-
tial therapeutic, moving the agent to the clinic usually requires
extensive animal testing. Thus good animal models have an impor-
tant place in the investigation of diseases of protein conformation.
Protein misfolding disorders come in a variety of ﬂavors. We
can describe them as genetic or acquired, intra or extracellular,
gain of function (GOF) or loss of function (LOF), localized or sys-
temic, with or without morphologically evident aggregates, neuro-
degenerative or not. Amyloidosis, the prototypic protein folding
disorder (or group of disorders), was noted in the mid-19th century
in autopsy specimens from patients with a diverse set of diseases
[1]. Each amyloid represented the detectable end product of many
pathologic processes culminating in a ﬁnal common pathway of
aggregation, ﬁbril formation and tissue deposition, although not
necessarily in that order.
Twenty-seven such proteins have been identiﬁed as amyloid
precursors in humans (Table 1). Further, in addition to the quanti-
tatively dominant ﬁbrillar component, all deposits regardless oflsevier B.V. All rights reserved.
Table 1
Amyloid ﬁbril proteins and their precursors in human.a Reprinted from Westermark et al. [120]. Permission pending.
Amyloid
protein
Precursor Systemic (S) or localized,
organ restricted (L)
Syndrome or involved tissues
AL Immunoglobulin light chain S, L Primary
Myeloma-associated
AH Immunoglobulin heavy chain S, L Primary
Myeloma-associated
Ab2M b2-Microglobulin S Hemodialysis-associated
L? Joints
ATTR Transthyretin S Familial
Senile systemic
L? Tenosynovium
AA (Apo)serum AA S Secondary, reactive
AApoAI Apolipoprotein AI S Familial
L Aorta, meniscus
AApoAII Apolipoprotein AII S Familial
AApoAIV Apolipoprotein AIV S Sporadic, associated with aging
AGel Gelsolin S Familial (Finnish)
ALys Lysozyme S Familial
AFib Fibrinogen a-chain S Familial
ACys Cystatin C S Familial
ABri ABriPP S Familial dementia, British
ADanb ADanPP L Familial dementia, Danish
Ab Ab protein precursor (AbPP) L Alzheimer’s disease, aging
APrP Prion protein L Spongioform encephalopathies
ACal (Pro)calcitonin L C-cell thyroid tumors
AIAPP Islet amyloid polypeptidec L Islets of Langerhans
Insulinomas
AANF Atrial natriuretic factor L Cardiac atria
APro Prolactin L Aging pituitary
L Prolactinomas
AIns Insulin L L Iatrogenic
AMed Lactadherin L L Senile aortic, media
AKer Kerato-epithelin L L Cornea, familial
ALac Lactoferrin L L Cornea
AOAAP Odontogenic ameloblast-associated
protein L
L Odontogenic tumors
ASemI Semenogelin I L L Vesicula seminalis
ATau Tau L L Alzheimer’s disease, fronto-temporal dementia, aging,
other cerebral conditions
a Proteins are listed, when possible, according to relationship. Thus, apolipoproteins are grouped together, as are polypeptide hormones.
b ADan comes from the same gene as ABri.
c Also called ‘amylin’.
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serum amyloid P-component (SAP), apolipoprotein E, and the pro-
teoglycan perlecan. The functions of these three molecules, with
respect to ﬁbril formation, are still obscure [2]. In addition to these
‘‘accessory proteins” some deposits, particularly those in the brain
(which have been studied in most detail) contain other molecules
which have been hypothesized to either enhance deposition or re-
tard the process [3].
In the two most common systemic human amyloidoses, i.e. AA
and AL, large amounts of precursor protein could be obtained from
human or animal body ﬂuids and the process of ﬁbril formation
could be studied in the test tube [4,5]. The development of recom-
binant molecular techniques made it possible to obtain large
amounts of pure precursor proteins responsible for most of the
clinical amyloid syndromes for in vitro studies of ﬁbrillogenesis.
In addition, incubation of a number of molecules associated with
neurodegenerative diseases, under amyloid ﬁbril forming condi-
tions in vitro revealed that they too behaved as did classical amy-
loid precursors under the same conditions [6]. Subsequently the
family of amyloid precursors was expanded to include all those
proteins that formed ﬁbrillar aggregates with the characteristic
b-sheet structure and dye-binding properties found in the original
extracellular disorders in vivo and in vitro.
There have been numerous studies on naturally occurring and
inducible animal amyloidoses including amyloid A in a variety of
species, scrapie in sheep, BSE in cattle, ApoAII isomorphs in theSenescence Accelerated Mice (SAM) and amyloid-containing insu-
linomas in cats [7]. To the extent that the same or similar condi-
tions occur in humans the animal disorders can serve as disease
models.
2. Murine models of the human amyloidoses
2.1. Amyloidosis A (AA)
In humans AA amyloidosis occurs as a consequence of chronic
inﬂammation, infectious or non-infectious. It is found in approxi-
mately 5% of patients with rheumatoid arthritis, an unknown pro-
portion of individuals with chronic infections and a signiﬁcant
proportion of non-Ashkenzi Jews with Familial Mediterranean Fe-
ver and individuals with other genetic abnormalities leading to
autoinﬂammatory disorders related to the innate immune system
[8].
With respect to the human systemic disorders, the inﬂamma-
tion inducible murine AA model in which susceptible strains of
mice were exposed to a variety of inﬂammatory stimuli (subcuta-
neous injections of casein, Freund’s adjuvant, turpentine, silver ni-
trate) had been studied long before recombinant proteins became
available [9]. The isolated ﬁbril was the ﬁrst non-immunoglobulin
characterized chemically, thus named Amyloid ‘‘A” [10]. The model
provided insight regarding the nature of the precursor, i.e. the ser-
um acute phase apolipoprotein SAA, and the role of inﬂammatory
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NFjB, with the subsequent generation of AA as the direct ﬁbril
forming precursor by proteolysis of SAA, apparently by macro-
phage proteases [11–14]. The model suggested that genetically
controlled differences in precursor structure could determine indi-
vidual susceptibility to amyloid deposition in response to a chronic
inﬂammatory stimulus. It also served as a test system for mole-
cules designed to inhibit tissue deposition by interfering with the
interaction between AA aggregates and matrix proteins that were
subsequently evaluated in human clinical trials [15,16].
The murine AA model has also raised the issue of whether
‘‘infectivity” plays a role in other forms of amyloidosis in addition
to the prionoses. It has been shown in many laboratories that injec-
tion of sonicated splenic extracts from mice with AA deposition,
when given in conjunction with an inﬂammatory stimulus, will
accelerate the appearance of amyloid ﬁbrils in a naïve recipient
from weeks to days [17]. The active component (originally known
as amyloid enhancing factor or AEF), which appears to serve as a
seed, is the growing end of the fragmented ﬁbrils. Amyloid A was
the ﬁrst form of systemic amyloidosis to display the seeding phe-
nomenon in vivo. Tissue deposition can also be accelerated by
the injection of ﬁbril fragments from a variety of sources including
fragmented ﬁbrils formed from transthyretin peptides, silk, and
bacterial curlin protein as well as AA ﬁbrils themselves [18]. It
has also been established that oral ingestion of such seeds may
serve as accelerants [19,20]. In principle this is felt to differ from
the infectivity of the true prion disorders, since in the case of pri-
ons, the animals would not get aggregation and deposition if they
did not see the scrapie conformer or a similar seed. Hence, there
may be a meaningful distinction between initiation (as seen in
the prionoses) and acceleration as seen with AEF and murine Apo-
AII (see below).
Transgenic technology has not played a major role in the inves-
tigation of AA disease. However, three sets of transgenic studies
have been informative in the investigation of AA pathogenesis. Re-
cently, it has been shown that, as expected, IL-6 transgenics will
develop AA amyloid deposition on the basis of increased SAA syn-
thesis and processing and such animals can be utilized in testing
for factors which accelerate the process [21].
In a second transgenic study over-expression of the gene encod-
ing heparanase revealed that shortening the length of the heparan
sulfate chains in matrix proteoglycans made animals resistant to
AA deposition [22]. In other AA related studies gene silencing has
been utilized to investigate the role of serum amyloid P-compo-
nent (SAP), the murine acute phase protein found in all amyloid
deposits, in the pathogenesis of AA amyloidosis in mice. Two inde-
pendent studies of separately derived strains in which its gene
(APCs) was silenced by targeted disruption, showed that inﬂamma-
tion-induced AA occurred at a moderately decreased rate relative
to controls, and that the rate of absorption of the deposits after
stopping the stimulus was no different in the SAP knockouts and
controls. Thus, despite being present in the deposits of all forms
of amyloid, SAP was not required for either ﬁbril deposition or sta-
bility in vivo [23,24]. One can envision experiments in which a
gene or genes encoding the protease(s) required for the processing
of the SAA precursor to AA might be silenced with a profound ef-
fect on the deposition phenotype. However, such experiments have
not been reported.
2.2. Apolipoprotein AII
A second naturally occurring animal amyloidosis was described
by Japanese investigators who, in the course of breeding sub-
strains of AKR mice to select for longevity, discovered that several
of their variant strains uniformly developed amyloid deposition
late in life [25]. This was not surprising since the increasing fre-quency of amyloid deposition with age had been previously noted
in human autopsies [26]. The amyloid consisted of intact apolipo-
protein AII [27]. Mouse strains bearing the amino acid glutamine at
position 5 (ApoA2c) were found to be susceptible to this form of
amyloidosis, while strains having proline in the same position
(ApoA2a or 2b) were not [28]. The potential for amyloidogenesis
could be transferred to a non-amyloid forming strain by making
it congenic for the amyloidogenic isoform [29]. While AA deposi-
tion was also found with aging in some strains of mice and some
mice had both forms, there did not appear to be cross-seeding in
the naturally occurring diseases. However, subsequent experi-
ments in which ﬁbrils or ﬁbril fragments were injected into ani-
mals representing each model suggested either an additive or
reciprocal relationship in the two forms of ﬁbril deposition [30].
These results, while interesting and suggesting that cross-seeding
can be induced experimentally, are not consistent with cross-seed-
ing in the natural course of either AA or ApoAII deposition in mice.
As in the AA model, injection or feeding of ApoAII ﬁbril fragments
could accelerate deposition [31]. The ApoAII amyloid could also be
transmitted by fecal ingestion or vertically during nursing [32].
Hence the phenomenology of acceleration by seeds was similar
to that seen in the AA model.
Many, but not all, amyloid precursors form ﬁbrils in a process of
nucleated polymerization [33]. Addition of small amounts of ﬁbril
fragments (seeds) to the in vitro reaction accelerates the process of
ﬁbrillogenesis [34]. It has been assumed that the association of var-
ious forms of amyloidosis with aging reﬂects a latent period during
which the seeds form. The seeding experiments in the AA and Apo-
AII models do not necessarily support this argument. In both these
systems the precursor (SAA or ApoAII) is present in very high
concentrations either as the result of inﬂammation (SAA) or in
response to diet ApoAII [35]. Both precursor molecules are apo-
lipoproteins, hence have a sufﬁcient degree of hydrophobicity to
be potentially unstable in aqueous media. Both are amyloidogenic
when freed from their HDL ligand. SAA requires cleavage to gener-
ate the structure that has optimal ﬁbril forming capacity. Inﬂam-
matory cells provide both a cellular source of appropriate
protease activity as well as the amyloidogenic substrate. These ap-
pear to be special cases, peculiar (but not exclusive) to the mouse.
The relatively high frequency of these conditions in particular
mouse strains and their relative rarity in humans may make them
less informative as models of human disease than interesting
experimental systems in their own right.
2.3. Prion diseases
The same can be said of the prionoses. Although the apparent
epidemic of variant Jakob-Creuzfeldt disease associated with the
ingestion of beef from animals with Bovine Spongioform Encepha-
lopathy (BSE or ‘‘mad cow disease”) and its genetic counterpart
(CJD) indicate that there is a human homolog [36]. Here again
much of the characterization of murine and hamster scrapie was
achieved well before the availability of transgenic animals. The no-
tion of ‘‘protein only infectivity” mediated by templated misfolding
of a native protein was a novel idea, which appears to be generally
correct [37]. Exposure via ingestion followed by transport to the
brain through lymphatics and a long incubation period is well
established although we are still far from full understanding of
the process. The demonstration of strain differences related to spe-
ciﬁc protein structures and the variability of such structures in a gi-
ven strain is under active investigation as is the basis for strain
differences in pathogenetic effects, i.e. more amyloid ﬁbril forma-
tion in some strains and more spongioform change in others
[38]. As in many of the pathogenic amyloidoses there is accumulat-
ing evidence that the mature ﬁbrils are not the toxic element
rather it is oligomeric pre-ﬁbrillar species that are the major path-
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but in vivo conﬁrmation remains an investigative goal.
Transgenic/knockout animals enabled the performance of the
critical experiments demonstrating that host speciﬁcity was a
function of the endogenous PrPc gene since murine PrPsc was not
pathogenic in mice in the absence of a functional PrPc gene [39].
Similarly the demonstration that BSE aggregates could affect mice
in which the endogenous PrPc had been replaced by its human
homolog was the best laboratory evidence for transmission of that
agent into humans [36].
2.4. AL amyloidosis
Transgenesis technology and its gene silencing variant have al-
lowed the development of a number of potentially relevant models
of human protein misfolding diseases but have not been fruitful for
some human amyloidoses. For instance there have been numerous
attempts to generate a transgenic model of the systemic amyloido-
sis related to immunoglobulin light chain deposition (AL). No suc-
cessful models have been reported, nor has the reason for the lack
of success been deﬁned, although it may be that the amyloidogenic
potential of a particular light chain structure can only be realized
when the protein is synthesized and secreted to a level equal to
or greater than the critical concentration required for its aggrega-
tion under physiologic conditions. In vivo this may require a degree
of clonal expansion that has not yet been achieved experimentally.
Transfection of the murine hybridoma parent cell line SP2 with
an amyloidogenic human light chain and injection of the cells into
a recipient animal was not experimentally useful since the SP2
cells grew too quickly to allow any analysis of the process of amy-
loid formation or deposition even if it had occurred.
The only model, which has had some success, is highly artiﬁcial
and involves injecting large amounts of an amyloidogenic precur-
sor light chain either intraperitoneally or under the skin [40]. A
mass forms consisting largely of ﬁbrillar material surrounded by
macrophages and neutrophils which is ultimately resorbed. The
host response to the mass suggested that an antibody directed to-
ward epitopes available on the aggregates might enhance the
inﬂammatory response and hasten clearing. This is a cumbersome
model that has little resemblance to the development of the dis-
ease in vivo. Nonetheless anti-amyloid antibodies have been gen-
erated that accelerate clearing of the deposits and have been
humanized for use in clinical trials [41].
2.5. Transgenic considerations
What kind of information would emerge from transgenic dis-
ease models that might be more difﬁcult or impossible to obtain
in other experimental systems? Since the extracellular amyloidos-
es are systemic, with deposition frequently taking place at location
distant from the site of synthesis an organismal rather than tissue
culture approach would seem to be favored. Models should allow
the development of more precise notions of pathogenesis and the
roles of proteins other than the actual precursor in facilitating or
inhibiting amyloid generation and deposition. In the most sophis-
ticated instances, gene replacement (knock in) technology allows
the replacement of a precursor molecule with a gene or exon
encoding an amyloidogenic sequence that differs from the original.
This approach has been utilized to demonstrate the requirement
for Cys10 in the V30 M TTR structure in order to achieve aggrega-
tion and deposition in V30 M TTR transgenic animals [42]. Such
experiments validate data obtained in vitro on the effects of spe-
ciﬁc structural changes on the process of ﬁbril formation.
The effects of genetic factors, not readily apparent in the human
diseases, in vitro or in tissue culture settings, can be assessed in
transgenic animals, particularly in crosses in which genes encodingpotentially interactive proteins are silenced (see above re:SAP
knockouts). Apolipoprotein E knockouts have been informative,
although not consistent, in studies of pathogenesis in Alzheimer’s
disease (AD) models [43]. Animal models lend themselves to test-
ing the roles of diet and other environmental factors on disease
development in the presence of a bona ﬁde precursor transgene.
The most obvious use is in the evaluation of therapies using both
small molecule and biologic approaches to prevention and
treatment.
What properties would we like in such models? Ideally one
would like the precursor to be driven by its endogenous promoter
so that its tissue expression reﬂects what occurs in vivo with re-
spect to known physiologic and environmental inﬂuences (so-
called ‘‘construct validity”). It would be preferable to have the gene
expressed at levels similar to those seen in vivo, usually achieved
by integration of a single functional gene copy or the diploid state
in a homozygous cross. This becomes particularly important in
models in which a therapeutic is designed to bind to the precursor
with a deﬁned stoichiometry. Multiple copy number models might
require much more drug for effect than would be necessary in pa-
tients in whom there may be only one or at most two genes encod-
ing the amyloidogenic protein. Thus an agent that might be
effective in patients might be ineffective or toxic in a model that
depended on overproduction of the amyloid precursor to obtain
the disease phenotype simply because there is too much precursor
(lack of ‘‘predictive validity”).
One would also like the model to display both clinical and path-
ologic phenotypes that resemble those seen in human patients
with the disease being modeled, including its temporal pattern of
development, i.e. more disease with increasing age in the case of
the age dependent amyloidoses and tissue distribution of deposits
(‘‘face validity”). Once it is established that the model reﬂects the
human disorder one would like to be able to accelerate its develop-
ment (without changing the responsible molecular events) so data
could be acquired in a more compressed time frame.
For some models, while mice offer the advantage of extensive
knowledge of their genetics, their small size makes certain types
of manipulations and studies difﬁcult. Some laboratories have cho-
sen to develop transgenic rat models for conditions in which these
issues (e.g. organ transplantation therapies) are serious consider-
ations [44]. In other circumstances lentiviral or adenovirus associ-
ated viral vectors encoding amyloidogenic alleles have been
injected intracerebrally under stereotactic control to target speciﬁc
brain regions. These methods are easier in rats but have now been
adapted to mouse studies as well. In addition the larger rat brains
allow more informative use of imaging technology.
For impatient investigators the introduction of amyloid precur-
sors into worms (Caenorhabditis elegans) and ﬂies (Drosophila mel-
anogaster) compresses the time necessary to obtain a disease
phenotype [45,46]. However, the relationship between that cellu-
lar and molecular phenotype and human disease may be problem-
atic. On the other hand the comparability of these post-mitiotic
model systems to mammalian post-mitotic tissues, such as neu-
rons or myocytes, suggests that the molecular aspects of some of
the models may be extremely useful in the analysis of those disor-
ders in more long-lived species. This has been evident in a series of
experiments in worms transgenic for a gene encoding a form of the
Huntington disease protein with a poly-Q region containing a
stretch of glutamines that does not normally aggregate. By silenc-
ing genes encoding various components presumed to be involved
in the handling of misfolded proteins the threshold for aggregation
is lowered and the pathologic phenotype appears [47]. While this
may not be an accurate ‘‘disease model” it allows detailed investi-
gation of cellular and molecular pathogenesis and could be used as
an in vivo screen for inhibitors that might be useful in the analo-
gous human disorders.
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the systemic amyloidoses exhibit ideal characteristics. While some
of the variation reﬂects general differences between humans and
mice (the details of which are not fully understood), some are a
consequence of particular features of murine molecules and their
interaction with transgene products [48].
2.6. The transthyretin (TTR) amyloidoses
There are three human disorders characterized by the extracel-
lular deposition of TTR aggregates, Familial Amyloidotic Polyneu-
ropathy (FAP), Familial Amyloidotic Cardiomyopathy (FAC) and
Senile Systemic Amyloidosis (SSA). The ﬁrst two are caused by
mutations. The last is the result of age dependent cardiac deposi-
tion of the wild-type protein. In each case the homo-tetramer re-
leases a monomer subunit, which misfolds and is subject to
aggregation and tissue deposition in its target organ [49]. What
determines the site of deposition of any of these proteins is still
unknown.
The original TTR transgenics utilized cDNA’s encoding the amy-
loidogenic allele V30 M TTR driven by the relatively promiscuous
metallothionein promoter. The animals showed early deposition
in all tissues in which the mRNA was identiﬁed, however in tissues
other than the liver and choroid plexus there was no expression of
the endogenous TTR gene, suggesting that such a construct would
not generate a useful disease model since it was being expressed in
tissues not normally synthesizing the protein [50]. The animals did
not develop peripheral neuropathy, the hallmark of the human dis-
ease. Subsequently the intact human gene with most of its known
regulatory sequences was reconstructed from two partial genomic
clones isolated from a human EcoR1 library made from an FAP pa-
tient and used to generate several additional transgenic strains
[51]. One of these contained 6.0 kb of sequence upstream of the
initiation site, which showed appropriate tissue speciﬁc expression
and tissue deposition (gut, heart, skin, and kidney) beginning at
about 1 year of age. These animals contained 30–60 copies of the
human gene, but still did not display peripheral or autonomic neu-
ropathy. Nonetheless they were considered moderately successful.
The role of environment had to be addressed when these trans-
genics were moved from a conventional animal facility to a speciﬁc
pathogen free facility. With that move the mice stopped develop-
ing tissue deposits to the same extent as previously [52]. As ex-
pected they showed a difference in the gastrointestinal ﬂora in
the two locales and hypothesized that some degree of inﬂamma-
tion was required to stimulate the formation of tissue aggregates
[53]. On the surface this explanation seems unlikely since hepatic
TTR synthesis, which is responsible for producing the bulk of circu-
lating TTR, the ﬁbril precursor, is down-regulated in the course of
inﬂammation by the action of inﬂammatory cytokines [54]. It is
also not clear whether genetic drift has been completely elimi-
nated as a proximal or contributory cause. Other TTR transgenics
in other laboratories have yielded perfectly valid phenotypes when
reared under SPF conditions.
Transgenics made from the wild-type and mutant TTR genes of
an individual carrying the highly unstable L55P TTR mutation pro-
vided several interesting insights into the nature of transgenic ani-
mal models. Both genes used to produce the transgenics were
cloned as 19.2 kb genomic fragments containing all the known reg-
ulatory sequences of the normal TTR gene [55]. Animals bearing
the wild-type gene contained 100 copies and displayed amyloid
deposition in the kidneys (80%) and the hearts (50%) after
18 months. Both strains showed tissue expression in the pattern
expected from studies in humans, i.e. liver, choroid plexus, eye,
gut and kidney. In the animals bearing the wild-type gene, males
showed greater deposition than the females. In both sexes younger
animals showed non-amyloid (diffuse) deposits in the same organsat an earlier age than the Congophilic deposits. The occurrence of
ﬁbrillar deposits seems to be both a function of TTR concentration
and age (duration of exposure) a phenomenon that was subse-
quently conﬁrmed in the human disease when non-ﬁbrillar TTR
deposits were found in the peripheral nerves of Portuguese pa-
tients with early FAP [56].
The age and gender dependent deposition of the wild-type pro-
tein resembles that seen in the human SSA disorder. Transcription
analyses of these animals indicated that cardiac deposition oc-
curred when the liver did not respond to the presence of the many
copies of wild-type TTR with an unfolded protein response (UPR)
and subsequent transcription of chaperone genes and elements
of the ubiquitin-proteasome system (Buxbaum et al., unpublished).
In animals with such a transcriptional response histologic cardiac
deposition did not occur and no oxidative stress response was seen
in the hearts. On the other hand, livers from animals with cardiac
deposits showed no UPR or chaperone response while their hearts
showed an exuberant transcriptionally mediated oxidative stress
response. At this time it is unknown whether the tissue responses
will be the same to the normal concentration of a thermodynami-
cally unstable TTR as they are to large amounts of the wild-type
protein. If the absolute amounts of misfolded TTR are equivalent,
representing a relatively large proportion of the total amount of
the unstable protein and a small proportion of the wild-type mol-
ecule, the processes should be similar. This remains to be proven
experimentally.
The strain derived from the mutant L55P TTR gene contained a
single copy of the gene and showed no deposition phenotype even
at 2 years of age in animals homozygous for the human construct.
Inoculation of these animals with ﬁbrils made from TTR peptides
that behaved as active AEF in the inﬂammation-induced AA model
did not result in the development of TTR deposits in these mice
[57,58]. In subsequent studies the mutation was crossed onto the
murine TTR knockout background. One-third of those animals
showed deposition suggesting that the murine TTR molecule inhib-
ited the aggregation and deposition of the highly unstable human
molecule [59]. Combined in vivo and in vitro studies subsequently
showed that in the presence of the murine TTR gene, highly stable
human-mouse hetero-tetramers were formed, thus reducing the
availability of the free human monomer precursor of the aggre-
gates [48]. Further experiments showed that administration of
diﬂunisal, a molecule that binds in the thyroxine binding pocket
of TTR and is currently in clinical trials in patients with FAP, stabi-
lized the human L55P molecule to denaturation by urea to the
same extent as did the murine protein in a fashion similar to that
seen when Portuguese V30 M TTR carriers also bear the T119 M
TTR allele in trans [60].
Other investigators have used the L55P allele in different molec-
ular settings to accelerate pathogenesis. When the animals were
crossed with HSF1 knockout mice that were unable to mount a
chaperone response, the offspring showed relatively early gastro-
intestinal deposits and, for the ﬁrst time, deposits in sciatic nerve
and dorsal root ganglia [61]. The demonstration that silencing a
critical transcriptional regulator of the unfolded protein response
accelerated disease conﬁrmed its involvement in protection
against tissue damage produced by TTR aggregates. What is not
clear from these studies is whether the absence of HSF1 is making
target cells more sensitive to toxicity of extracellular aggregates,
whether its impact is on the liver’s capacity to adequately chaper-
one misfolded TTR synthesized in the hepatocyte or whether TTR is
being made in dorsal root ganglia and the absence of HSF1 results
in cell death based on aggregation of locally synthesized TTR?
A transgenic strain has also been constructed using the gene
encoding I84S TTR, a very interesting mutation in which the TTR
retinol binding protein interaction site is disrupted. Neither amy-
loid nor diffuse TTR deposits have been seen in these animals over
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out background [62]. These animals appear to carry 8–10 copies of
the human gene. They have been used as a model system in which
to test the efﬁcacy of TTR anti-sense to speciﬁcally silence tran-
scription of the mutant allele [63]. Since these animals have no
deposition phenotype the effect of such silencing on deposition
cannot be judged. Successful silencing would provide proof of prin-
ciple of the approach to show that production of the protein can be
diminished in the liver.
Thus it is quite clear that murine transgenic models of the TTR
amyloidoses have provided interesting insights into the pathogen-
esis of the human disorders which they were generated to model.
However, the necessity for over-expression to overcome the stabil-
ity of murine-human hetero-tetramers and the apparent differen-
tial processing of misfolded-prone proteins between humans and
mice or the need to cross the animals onto mice that have deletions
in genes with major homeostatic functions other than simply chap-
eroning the amyloid precursor, have made them less than optimal
tools for either ﬁne analysis or experimental therapies. There have
been recent successful efforts to ‘‘knock in” human TTR transgenes
into the murine TTR locus [64]. It remains to be seen whether
experiments with these strains can overcome the experimental
disadvantages of the earlier models.
2.7. Islet amyloid polypeptide (Amylin, IAPP)
Homogeneous eosinophilic deposits were ﬁrst described in the
pancreas at autopsy of diabetic humans in 1901. Their amyloid nat-
ure and association with aging in diabetics taking insulin was
established in autopsy series much later and the identiﬁcation of
the ﬁbril as IAPP or amylin almost simultaneously by two laborato-
ries in the mid-1980s [65,66]. This is a localized form of amyloid
with systemic effects thus is probably best studied in an organis-
mal context. Comparative structural studies showed that the ami-
no acid residues 20–29 were critical for the amyloidogenicity of
the 37 amino acid mature peptide. Proline at position 28, the res-
idue found in mouse, rat and hamster, was anti-amyloidogenic
[67]. This observation prompted several laboratories to create
transgenic mouse lines, correctly assuming that there would be
no endogenous IAPP amyloidogenesis to confuse the interpretation
of the data.
Since it had previously been established that insulin and IAPP
were co-expressed and secreted by the pancreatic b-cell each lab-
oratory used some form of the rat insulin promoter to drive human
IAPP cDNA [68–71]. In some laboratories intron ﬁllers derived from
either globin or albumin were used with the purpose of enhancing
functionality of the transgene. The number of integrated copies of
the human construct was not speciﬁcally noted in any of the re-
ports. Strain backgrounds varied with FVB/N, C57Bl/6 and C57Bl/
6  DBA/2 all being used as hosts, with subsequent crosses onto
a variety of backgrounds to determine the effects of other genes
(e.g. ApoE, Agouti, Ob/Ob) [72,73]. The endpoints for all were in-
creased IAPP concentrations in the serum, human IAPP staining
in b-cells, pancreatic amyloid deposition with ﬁbrils derived from
human IAPP and hyperglycemia or overt diabetes. Beta cell IAPP
synthesis was shown in some of the transgenic animals in virtually
all the experiments. Increased serum IAPP was also frequent. How-
ever, in only one model did pancreatic amyloid develop without
further experimental manipulation [70]. It was ultimately estab-
lished that procedures that increased insulin resistance (glucocor-
ticoids, high fat diets, mating with obesity predisposed strains) all
increased the frequency of pancreatic amyloid deposition, b-cell
loss and hyperglycemia [74,75]. More reﬁned analyses have sug-
gested that non-ﬁbrillar aggregates were cytotoxic, in some mod-
els inducing b-cell loss prior to signiﬁcant formation of mature
amyloid deposits [76].As a disease model these animals have validated the notion of
IAPP amyloidosis as playing a role in the pathogenesis of type II
diabetes. While relative or absolute insulin insufﬁciency may be
primary the subsequent insulin resistance stimulates the co-
expression of the IAPP and insulin genes. In these models the mag-
nitude and cell site of that expression was insured by driving the
IAPP construct with an insulin promoter. Since it has been shown
in vitro that insulin as well as rat and presumably mouse IAPP in-
hibit human IAPP ﬁbril formation (chaperone) perhaps it is the rel-
ative amount of each set of molecules that determines the rate and
extent of oligomerization and ﬁbril formation and accounts for the
variability among the different transgenic strains. One of the vari-
ables in disease development might be the presence of mixed hu-
man/rodent IAPP aggregates that are less ﬁbrillogenic than homo-
IAPP complexes in a fashion similar to that seen with human/mur-
ine TTR hetero-tetramers. These models continue to be explored
with the notion that stabilizing IAPP will reduce the rate of b-cell
loss and make molecules that enhance insulin production and re-
lease or reduce peripheral insulin resistance more effective, thus
increasing the effectiveness of treatment.
2.8. Gelsolin
Gelsolin is the precursor protein in the Finnish form of Familial
Amyloidotic Polyneuropathy, which is associated with skin, facial
nerve, cardiac and renal amyloid deposition [77]. It represents an-
other variation on the theme of systemic amyloidosis. In this in-
stance synthesis and deposition of the precursor occurs at
multiple sites. In the human disorder a mutation at position
D187 to N or Y (D187 N/Y) in plasma gelsolin compromises
Ca2+-binding in domain 2 enabling aberrant cleavage by furin gen-
erating a secreted 68 kDa fragment (C68) that can be further
cleaved in the extracellular space by a type I matrix metallopro-
tease, such as MT1-MMP, to generate the major (8 kDa) and minor
(5 kDa) amyloidogenic fragments that deposit in the tissues [78].
A single transgenic strain has been reported in which the mutant
gelsolin has been expressed in C57Bl/6 mice under the control of a
creatine kinase promoter in the context of a 50 globin intron and a
bovine growth hormone poly A site (Page et al., PNAS, USA, in
press).
As expected, because of the promoter choice, gelsolin synthesis
was seen only in cardiac and skeletal muscle. Congophilic gelsolin
deposits were found in capillaries and the skeletal muscle endo-
mysium. Deposition increased with age. The model appears to
faithfully reproduce the molecular events resulting in the same
amyloidogenic fragments seen in the human disease but results
in both extra and intracellular aggregates rather than only the
extracellular deposits described in human gelsolin amyloidosis.
Pathologically vascular disease is less prominent and the muscle
lesions of the animals appeared to be more like inclusion body
myositis, a sporadic muscle disease of the elderly in which a vari-
ety of ﬁbrillogenic proteins have been found to be deposited, the
most prominently described of which has been Ab [79].
2.9. Alpha-1-anti-trypsin (AAT) (Z-variant) deﬁciency
While not originally recognized as a protein misfolding disorder
and certainly not having any of the characteristics of the systemic
amyloidoses, i.e. Congophilic extracellular deposition at locales
distant from the site of synthesis, homozygous AAT deﬁciency
has the characteristics of both an LOF and GOF mutation [80].
The affecteds have diminished levels of a speciﬁc circulating serpin
(serine protease inhibitor), exhibit recurrent pulmonary disease
and ultimate respiratory failure because of excessive neutrophil
elastase activity in the lungs causing destruction of lung tissue. It
is an LOF disorder and belongs to the class of serpinopathies.
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different from that in the amyloidoses. The effect of the mutation
is to interfere with the generation of the active site in which the
target protease must ﬁt allowing insertion of the domain of
another AAT molecule to form a dimer with subsequent homo-
polymer propagation. A similar mechanism has been proposed
for neuroserpin in the dementia familial encephalopathy with
inclusion bodies (see below).
The Z-variant is one of the few examples of intracellular aggre-
gation of a protein normally secreted by hepatocytes, since the li-
ver cell seems to be particularly well-suited to deal with
potentially misfolded proteins, e.g. TTR mutants. The AAT liver dis-
plays intracellular inclusions, hepatocyte loss, ﬁbrosis and an in-
creased frequency of hepatocarcinoma. All of these features have
been recapitulated in the transgenic models of the disease
[81,82]. Further it has been possible to treat these animals with
small molecules that behave like molecular chaperones [83].
2.10. Neurodegenerative protein misfolding diseases
We have characterized the neurodegenerative protein misfold-
ing diseases as extrinsic, i.e. the prionoses, or intrinsic, i.e. indepen-
dent of external agents. The latter constitute the majority of the
described disorders. In these diseases the precursor is synthesized
and misfolds either within or in proximity to the target of its tox-
icity. Conceptually these disorders should be readily approachable
using tissue culture techniques rather than requiring animal mod-
els, since all the action is taking place in a conﬁned space. The util-
ity of animal models relates to two features of most of these
disorders. To some extent they are all age dependent, a quality dif-
ﬁcult to establish in tissue culture. Further, it is desirable to ulti-
mately validate any molecular observation with a behavioral
readout. Thus a variety of animal models of Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, Tauopathies, ALS have
been generated and extensively employed in a variety of settings
and have been the subjects of many excellent reviews [84–89].
2.11. Alzheimer’s disease (AD)
In many ways the attempts to make useful murine transgenic
models of human AD although imperfect, have been among the
most informative. Over the last several years there have been
excellent detailed reviews of these models to which the reader
can refer for speciﬁc information [90–93]. I will not review them
here except to draw general lessons, some of which have been dis-
cussed with respect to the systemic amyloidoses in earlier sections.
Lesson number 1: mice are not humans. We should not expect
the expression of a human disease-associated gene in a mouse to
precisely duplicate the human disease of interest. For instance,
while Tau phosphorylation has been seen in some transgenics
bearing either a mutant Ab gene or a combination of mutant Ab
and mutant presenilin 1 (PS-1) genes, neuroﬁbrillary tangles (a
characteristic feature of human AD) are only seen consistently in
the triple transgenics that also carry a Tau mutation [94–96].
Few studies have been directed at examining differences between
mice and humans with respect to deﬁning systematic guidelines
applicable to all or most transgenic models.
Lesson number 2: Phenotypes produced by insertion of a trans-
gene encoding a GOF protein are quantitatively much more dose-
dependent than models in which a gene deletion was generated
to reﬂect a LOF disorder. While homozygous gene deletions may
be embryonic lethal and hemizygotes give a survival disease phe-
notype in ‘‘LOF” models, the number of copies of a transgene
encoding a GOF protein can determine whether the disease pheno-
type is penetrant in the model, its temporal development and its
severity, since in general the level of protein production parallelsgene copy number. It is not clear why over-expression is required
in many or all of these models. It is possible that murine cells, par-
ticularly neurons, are better equipped to chaperone or dispose of
misfolded proteins than human cells of similar lineages, although
there are no quantitative data addressing this question.
Lesson number 3: Genetic background makes a difference. The
same mutation carried in different mouse strains may show sub-
stantial variation in phenotype, from no disease to early death in
some cases [97]. This should not be surprising since humans are
not inbred (for the most part) and could be used to an advantage
in understanding the pathology by mapping the responsible con-
tributory loci. The corollary from human genetics is that ‘‘there
are no single gene diseases”. For instance Familial Amyloidotic Pol-
yneuropathy (FAP) caused by the V30M TTR mutation behaves as
an autosomal dominant disease (see above). Yet the penetrance
is similar in Japanese and Portuguese carriers but far less so in
Swedes with the same mutation [98]. Even within the Portuguese
population the age of onset of disease can vary dependent on
which parent contributes the mutant allele as well as genetic var-
iation at other loci that may be involved in pathogenesis [99,100].
Lesson number 4: Environment matters. Variation in phenotype
from laboratory to laboratory reﬂecting differences in diet, hus-
bandry, maintenance and factors that have not yet been elucidated
can all impact on disease expression and the potential validity of
the model [52,101,102].
Lastly is the element of publication bias, i.e. the published pa-
pers are much more likely to document successfully generated
transgenic strains than those in which no phenotype was obtained.
2.12. Cystatin C (cerebral amyloid angiopathy) or hereditary cerebral
hemorrhage with amyloidosis, Icelandic type (HCHWA-II)
Many of the human amyloidoses affect blood vessels. In this
condition a mutation in Cystatin C, a cysteine protease inhibitor,
Leu68Gln, causes it to dimerize by a process thought to involve do-
main swapping followed by aggregation within the walls of cere-
bral blood vessels [103]. The aggregation is associated with
multiple cerebral hemorrhages in the carriers. However, mice
made transgenic for the human mutant allele with signiﬁcant
over-expression did not display Congophilic angiopathy [104].
Immunohistochemical analysis of AD brains has shown the
presence of cystatin C in both plaques and cerebral vessels. When
wild-type cystatin mice were crossed with the APP23 AD model
mice there was a 50% reduction in cortical plaques, a 50% reduction
in Ab1–40 and a 25% reduction in Ab1–42 concentrations in the brain
at age 14.5 months. Similar effects were seen when the cystatin C
animals were crossed with the TG2576 AD model mice. These
experiments are consistent with in vitro experiments showing
direct binding of cystatin C to Ab1–40 and Ab1–42 with inhibition
of ﬁbril formation [104].
2.13. BRI2 related dementias
Mutations in the BRI2 gene have been identiﬁed in familial Brit-
ish Demential and familial Danish dementia [105,106]. A point
mutation (FBD) and a decamer duplication (FDD) allow read
through the normal stop codon to yield a protein 11 amino acids
longer than in the native type II transmembrane protein. Furin type
proteolysis generates a 34 amino acid ﬁbril precursor which forms
Congophilic vascular deposits (Congophilic angiopathy) ‘‘soft”
parenchymal plaques and ﬁbrillar deposits in the brains of the car-
riers. Attempts to generate a transgenic model for FBD were not
successful [107]. However, transgenic animals produced by using
a cDNA enoding the Danish BRI2 extended sequence driven by
the murine prion protein promoter injected into C3HeB/FeJ
oocytes, subsequently bred into C57Bl/6 for 10 generations,
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and diffuse antibody positive deposits and gliosis were seen in
the regions of the deposits [108].
When Adenovirus Associated Viral vectors containing se-
quences encoding the BRi2 protein were injected intracerebrally
into AD model mice the neuropathologic features of AD were sup-
pressed [109]. These studies were consistent with in vitro experi-
ments showing that BRI2 bound to amyloid b precursor protein
interfering with its processing by secretases [110,111]. Hence like
cystatin C, the wild-type form of the amyloidogenic precursor
interferes with molecular events involved in AD pathogenesis.
2.14. Familial encephalopathy with neuroserpin inclusion bodies
(FENIB)
In 1996 a kindred was reported with dementia beginning in
their 40’s, apparent autosomal dominant inheritance and the strik-
ing appearance of neuronal inclusion bodies in the cortex and else-
where [112]. The inclusions were unique (Collins bodies) and were
found to be composed of aggregates of the serine protease tissue
plasminogen activator inhibitor neuroserpin. Mutations in the
gene were identiﬁed in independent kindreds (P112, S52R, S49P).
The wild-type gene was subsequently identiﬁed immunohisto-
chemically in AD plaques. In vitro incubation of the wild-type pro-
tein with amyloidogenic Ab peptides inhibited ﬁbril formation and
their cytotoxic effect on PC 12 cells [113].
Transgenic ﬂies were generated using the wild-type gene [113].
Interestingly these ﬂies were embryonic lethal when expressed
throughout the larvae and generated a mutant eye phenotype
when controlled by the GAL4GMR promoter. When the ﬂies were
crossed with ﬂies transgenic for Ab1–42 the embryonic lethal phe-
notype was abolished, indicating that the Ab interaction inhibited
the protease inhibitory activity of the serpin molecule. Although
the in vitro experiments indicated that Ab ﬁbril formation was
inhibited by the interaction, effects on the Ab phenotype of the ﬂies
were not reported.
2.15. Gelsolin, transthyretin and AD
The apparently inhibitory interactions of wild-type Cystatin,
BRI2 and Neuroserpin with Ab to reduce ﬁbril formation are inter-
esting since mutants of each of these proteins are ﬁbril or aggre-
gate precursors in vivo and all have been found associated with
plaques in AD brains. Studies have also been reported in which ani-
mals transgenic for wild-type gelsolin, apparently expressed only
in the liver (after hydrodynamic injection of a wild-type gelsolin
cDNA) reduced cerebral Ab burden, a phenomenon attributed to
the peripherally synthesized gelsolin behaving as a ‘‘plasma sink”
for potentially amyloidogenic Ab peptides [114]. A gelsolin-Ab
interaction has also been demonstrated in vitro [115]. These stud-
ies require further conﬁrmation.
Analysis of the interaction between wild-type transthyretin and
Ab in vitro have shown interaction between the two proteins as
well as inhibition of ﬁbril formation independently in several lab-
oratories [116,117]. APP23 AD model animals transgenic for TTR
show suppression of both the neuropathologic and behavioral phe-
notypes, while silencing of the endogenous TTR gene accelerated
the development of the characteristic neuropathologic ﬁndings in
two different murine AD models [118,119].
Do these interactions in vitro merely reﬂect the legendary stick-
iness of the Ab1–40 and Ab1–42 peptides or are they biologically
meaningful? Perhaps they indicate that wild-type proteins that
are predisposed to become amyloidogenic in the presence of a
structure-perturbing amino acid substitution share a set of physi-
cal properties that on the one hand predispose to aggregation,
but under relatively physiologic conditions are capable of reactingwith similar proteins in a manner that allows both to assume (or
re-achieve) native stable conformations. Are the effects in the
transgenic models only properties of these relatively artiﬁcial sys-
tems or do they reﬂect in vivo interactions that play a role in the
pathogenesis of human AD? Obviously these observations could
not have been made in the absence of animal models of AD. In or-
der to fully establish these phenomena as relevant for these and
other proteins it would seem that an in vitro interaction must be
observed with recombinant forms of the proteins with reasonable
stoichiometry. Inhibition of ﬁbril formation should be clear.
Expression of a transgene encoding the putatively interacting pro-
tein should impact on the pathology and physiology of the model
disease and silencing of the endogenous gene should have the
opposite effect on the disease phenotype. All should be conﬁrmed
in more than one laboratory. Lastly, or perhaps ﬁrstly, there should
be some evidence that there is a relationship of the protein in ques-
tion to the human disease. To date this has only been achieved for
the interaction between TTR and Ab.
3. Coda: are the models worth the time and trouble?
Each animal model is akin to a single patient. To the extent that
we can examine the organismal effects of what may be a single
mutation in a single protein they are useful. Whether they can pro-
vide the same mechanistic insights as cultured cells of the appro-
priate lineage is less certain for many of the disorders. They
certainly afford the opportunity to examine gene-gene interactions
and allow the detection of effects at a distance. They raise mecha-
nistic questions that may ultimately only be answered in more
reductionist experimental systems. Given those attributes the
investigator must decide whether the transgenic or other animal
model approaches are suitable to address their particular biologic
problem.
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